ASO Author Reflections: Immune-related adverse events during neoadjuvant chemoimmunotherapy for triple-negative breast cancer may influence time to adjuvant radiation Editorial

  

Authors:	Myers, S. P.; Downs-Canner, S. M.
Title:	ASO Author Reflections: Immune-related adverse events during neoadjuvant chemoimmunotherapy for triple-negative breast cancer may influence time to adjuvant radiation
Keywords:	unspecified side effect; cancer adjuvant therapy; cancer radiotherapy; neoadjuvant therapy; radiotherapy, adjuvant; antineoplastic agent; cancer immunotherapy; antineoplastic combined chemotherapy protocols; pathology; postoperative complication; immunotherapy; neoadjuvant chemotherapy; drug therapy; adjuvant radiotherapy; therapy; adverse event; triple negative breast cancer; procedures; chemoimmunotherapy; time to treatment; time-to-treatment; humans; prognosis; human; female; article; pembrolizumab; triple negative breast neoplasms
Journal Title:	Annals of Surgical Oncology
Volume:	31
Issue:	8
ISSN:	1068-9265
Publisher:	Springer
Date Published:	2024-08-01
Start Page:	5205
End Page:	5206
Language:	English
DOI:	10.1245/s10434-024-15445-z
PUBMED:	38776008
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85193807817&doi=10.1245%2fs10434-024-15445-z&partnerID=40&md5=28e70f90e1eb7187cbcea505f553ec48
Notes:	Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/217620